Ingmar Gorman

Ingmar Gorman

PhD in Clinical Psychology

EPIC, Lykos Therapeutics, Fluence, PsychedelicsEurope, MAPS, Horizons

Location: Prague, Czech Republic / Florida, USA

Ingmar Gorman, PhD, is a licensed psychologist, researcher, educator, and leader in the field of psychedelic-assisted psychotherapy. He maintains a private psychotherapy practice serving clients in New York, specializing in trauma, anxiety, depression, and substance use disorders. His clinical work integrates evidence-based approaches with relational and harm reduction psychotherapy.

Dr. Gorman has played a significant role in advancing the training, research, and clinical implementation of psychedelic-assisted therapies. He is the co-founder and former CEO of Fluence, an organization dedicated to training mental health professionals in psychedelic-assisted psychotherapy. He has contributed to therapist training, treatment manuals, and clinical research programs involving MDMA, psilocybin, and other psychedelic compounds, collaborating with organizations including Lykos Therapeutics, Beckley Psytech, ATAI, Tryp Therapeutics, Cybin, and MAPS.

He currently serves as Director of Clinical Implementation & Training for the European Platform for Integration of MDMA in Mental Health Care (EPIC), where he works with scientific, clinical, and policy leaders to develop responsible pathways for integrating MDMA-assisted psychotherapy into European healthcare systems. He is also an advisor to PsychedelicsEurope and a board member of Journey Clinical.

Dr. Gorman is co-author of The Psychedelic Therapy Workbook (New Harbinger, 2025) and is a frequent speaker and educator on psychedelic-assisted psychotherapy, therapist training, clinical ethics, and the translation of research into clinical practice. His work emphasizes the importance of therapeutic relationships, clinical competence, and thoughtful integration of emerging treatments into established systems of mental healthcare.

https://www.ingmargorman.com/